PulseAugur
EN
LIVE 00:38:47
中文(ZH) 中源协和：VUM02注射液I期临床试验首例受试者完成入组给药

Zhongyuan Huaxue enrolls first patient in VUM02 Injection trial; Kangtuo Medical sees executive resignation

By PulseAugur Editorial · [1 sources] ·

Zhongyuan Huaxue has announced that the first participant in the Phase I clinical trial for its VUM02 Injection has completed enrollment and dosing. This injection is being developed for acute graft-versus-host disease. The company has invested approximately 8.3 million yuan in the project as of May 2026. Separately, Kangtuo Medical announced that its Deputy General Manager, Li Fang, has resigned due to personal reasons. AI

IMPACT Minimal direct impact on AI operations; primarily relates to pharmaceutical development and executive changes.

RANK_REASON The primary news is a clinical trial enrollment for a drug, which falls under product development but is not a frontier release. The secondary news is an executive resignation.

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Zhongyuan Huaxue enrolls first patient in VUM02 Injection trial; Kangtuo Medical sees executive resignation

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Tool
The primary news is a clinical trial enrollment for a drug, which falls under product development but is not a frontier release. The secondary news is an executive resignation.
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product, other
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
52 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Zhongyuan Huaxue: First Subject Enrolled and Dosed in Phase I Clinical Trial of VUM02 Injection

    36氪获悉，中源协和公告，公司全资子公司武汉光谷中源药业有限公司自主研发的VUM02注射液，用于激素治疗失败的II度至IV度急性移植物抗宿主病的I/II期临床试验，其I期多次给药首例受试者已于2026年7月17日完成入组给药。截至2026年5月，该项目累计研发投入为830.89万元。

RELATED ENTITIES

RELATED TOPICS